• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

AbbVie - Articles and news items

AbbVie receives CHMP positive opinion for Hep C tablet combination

Industry news / 2 March 2017 / Niamh Marriott, Digital Editor

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV) and minimal to moderate fibrosis. […]

NICE does not recommend AbbVie’s leukaemia drug

Industry news / 16 February 2017 / Niamh Marriott, Digital Editor

The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range…

The Top 21…wealthiest pharma companies

Blog, Z Homepage promo / 6 February 2017 / Niamh Marriott, Digital Editor

Find out who made it to the top of our list of richest pharma companies…

study

Sanofi and Regeneron’s rheumatoid arthritis drug shows superior results

Industry news / 21 November 2016 / Niamh Louise Marriott, Digital Content Producer

Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab…

AbbVie’s Hep C drug achieves high SVR rates after just 8 weeks of treatment

Industry news / 18 November 2016 / Niamh Louise Marriott, Digital Content Producer

In more than 700 genotype 1-6 chronic HCV infected patients, 97.5% achieved sustained virologic response at 12 weeks, regardless of baseline viral load…

AbbVie receives CHMP positive opinion for Venclyxto (venetoclax) to treat chronic lymphocytic leukaemia

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

The CHMP recommends approval of venetoclax monotherapy in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have…

AbbVie’s HCV regimen receives FDA breakthrough designation

Industry news / 30 September 2016 / Niamh Louise Marriott, Digital Content Producer

For the investigational, pan-genotypic regimen of glecaprevir /pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C…

AbbVie’s 8 week clinical trial speedy and successful for 98% of Hep C patients

Industry news / 28 September 2016 / Niamh Louise Marriott, Digital Content Producer

The primary endpoint of the trial being the percentage of patients who achieved a sustained virologic response 12 weeks after treatment (SVR12)…

grazoprevir/elbasvir

AbbVie receives FDA approval for new Hepatitis C drug

Industry news / 27 July 2016 / Niamh Louise Marriott, Digital Content Producer

US FDA has approved Viekira XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the treatment of chronic genotype 1 (GT1) hepatitis C…

Samsung Bioepis seeks EU approval for its biosimilar adalimumab candidate, SB5

Industry news / 18 July 2016 / Victoria White, Digital Content Producer

At an estimated $4billion a year, the reference product, Humira, is among the European Union’s largest single drug expenditures…

AbbVie announces study data for Humira in fingernail psoriasis

Industry news / 7 July 2016 / Victoria White, Digital Content Producer

Nearly half of adult patients treated with Humira achieved at least a 75% improvement in their fingernail psoriasis compared to patients receiving placebo…

EC grants marketing authorisation for Zinbryta in multiple sclerosis

Industry news / 5 July 2016 / Victoria White, Digital Content Producer

The approval of Zinbryta is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +